Butylone (β-keto-MBDB, bk-MBDB) is a synthetic entactogen and stimulant of the cathinone and phenethylamine chemical classes, structurally related to MDMA through the addition of a beta-ketone group to the MBDB (N-methyl-1,3-benzodioxolyl-2-butanamine) backbone. It belongs to the MDxx cathinone family alongside methylone, ethylone, and mephedrone, sharing their combination of stimulant and mild entactogenic properties.
Butylone acts as a mixed reuptake inhibitor and releasing agent for serotonin, dopamine, and norepinephrine — the same three monoamine neurotransmitters targeted by MDMA, but with important differences in relative potency at each transporter. Compared to MDMA, butylone has significantly weaker serotonergic activity relative to its dopaminergic effects, meaning the empathogenic, emotionally warm qualities characteristic of MDMA are present but subdued, while stimulant qualities are more prominent. Users describe an experience with moderate euphoria, mild sociability enhancement, increased energy, and some emotional opening — positioned between a stimulant and an entactogen, closer to the stimulant end.
Duration is typically shorter than MDMA — 2–4 hours for primary effects — and the overall intensity is generally considered milder. The comedown is less pronounced than with MDMA in part because the serotonergic depletion is less severe. However, stimulant-related comedown effects (fatigue, mild dysphoria, sleep disruption) are present.
Like other cathinones in the MDxx family, butylone carries entactogen risks — serotonergic toxicity potential in combination, neurotoxic risk with heavy repeated use — in addition to the cathinone-class stimulant risks of cardiovascular stress and compulsive redosing. It is substantially less researched than MDMA, meaning the full safety profile remains incompletely characterized. Harm reduction approaches developed for MDMA provide a reasonable baseline but cannot be assumed to transfer perfectly.
Safety at a Glance
High Risk- Test Your Substance
- Butylone cannot be distinguished from MDMA by appearance. Reagent testing is essential:
- Toxicity: Overview Butylone's toxicity profile combines elements of entactogen and stimulant risk. As a less potent, less exten...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: Stimulant overdose from Butylone is a medical emergency primarily involving cardiovascular and ne...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 3 hrs – 5 hrsHow It Feels
The onset of butylone arrives within thirty to sixty minutes as a gentle, familiar warmth. There is a mild quickening of the pulse, a softening of mood, and a subtle inclination toward sociability that echoes its more famous relative without matching its intensity. The body feels slightly lighter, and there is a quiet optimism building in the background of awareness, a sense that the evening holds pleasant possibilities without any guarantee of revelation.
As the effects develop, butylone settles into a mild empathogenic state. Social warmth increases by a modest degree: conversations feel slightly more engaging, people seem slightly more likeable, and the usual self-conscious filters that govern social behavior relax by a fraction. Touch sensitivity is mildly enhanced, and music sounds a little richer. But these are gentle augmentations rather than transformations. The stimulant component provides a light energy that keeps the user alert and engaged without producing restlessness or driven activity. The jaw may tighten slightly, appetite diminishes, and there is a mild increase in body temperature.
At the peak, roughly ninety minutes to two hours in, butylone reveals its fundamental character as a diluted echo of MDMA. The empathogenic warmth is real but restrained. The euphoria is present but understated. The headspace remains clear and functional, with none of the overwhelming emotional intensity that defines stronger empathogenic substances. Physical effects are proportionally mild: moderate jaw tension, slight pupil dilation, and a comfortable warmth in the body. The experience is pleasant enough to enjoy but unlikely to produce the profound emotional connections or insights that characterize peak empathogenic experiences.
The decline begins around three to four hours in and is smooth and uneventful. The mild warmth fades gradually, energy levels normalize, and baseline mood returns without any dramatic transition. The comedown is notably gentle, one of butylone's genuine advantages over more potent compounds. There is little serotonergic depletion to contend with, and the following day is typically unremarkable. Sleep arrives without difficulty, appetite returns normally, and there are few if any residual effects. The total experience is pleasant, sociable, and ultimately modest, a low-stakes introduction to empathogenic territory.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(17)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Nystagmus— Rapid, involuntary oscillating movements of the eyes that cause vision to vibrate and blur, often ma...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
- Vibrating vision— Vibrating vision is the subjective experience of the visual field rapidly oscillating or shaking due...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(1)
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
Cognitive(14)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Mindfulness— Mindfulness in the substance context refers to a state of heightened present-moment awareness in whi...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
Butylone acts as a mixed monoamine reuptake inhibitor and releasing agent, targeting the serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET). This mechanism is qualitatively similar to MDMA, but the quantitative balance differs: butylone has relatively less potent SERT activity and a higher DAT:SERT ratio than MDMA, producing a profile shifted toward stimulation and away from pure entactogenesis.
The beta-ketone modification that distinguishes butylone from MBDB (its non-cathinone counterpart) reduces lipophilicity and blood-brain barrier penetration compared to the parent compound, contributing to the lower overall potency and partially altered pharmacological profile compared to non-cathinone analogs.
Serotonergic Component
Despite weaker SERT activity than MDMA, butylone retains clinically relevant serotonergic activity. This means:
- Entactogenic and empathogenic qualities are present, though milder than MDMA
- Risk of serotonin syndrome in combination with other serotonergic agents (MAOIs, SSRIs, other entactogens) is real
- Some degree of post-use serotonergic depletion contributes to comedown effects
Dopaminergic and Noradrenergic Component
The relatively prominent dopamine and norepinephrine reuptake inhibition contributes to the stimulant character of butylone — energy, motivation, focus — and also underlies:
- Cardiovascular stimulation (heart rate and blood pressure elevation)
- Appetite suppression
- The reinforcing and compulsive redosing potential
Pharmacokinetics
Butylone is typically active at 100–250mg doses when taken orally. Onset is 30–60 minutes, with peak effects at 60–120 minutes, and primary effects lasting 2–4 hours total. The shorter duration compared to MDMA (which lasts 3–5 hours) is a practical distinction in use patterns.
Detection Methods
Standard Drug Panel Inclusion
Butylone is a substituted cathinone (synthetic cathinone) that is not included on standard 5-panel or 10-panel immunoassay drug screens. Some extended panels (particularly those marketed for "bath salts" detection) may include cross-reactive antibodies for the cathinone class, but coverage is inconsistent. The structural relationship to amphetamine means some cathinones trigger the amphetamine channel on immunoassays, but this is compound-specific and unreliable for Butylone.
Urine Detection
Butylone and its metabolites can typically be detected in urine for 2 to 4 days following a single dose. Repeated or binge-pattern use may extend this window to 5 or more days. Primary metabolic pathways involve reduction of the beta-keto group, N-dealkylation, and hydroxylation. The resulting metabolites are excreted renally, often as glucuronide or sulfate conjugates.
Blood and Saliva Detection
Blood detection windows for Butylone range from 12 to 48 hours depending on dose and individual metabolism. Plasma concentrations decline rapidly due to extensive distribution into tissues. Oral fluid testing can detect Butylone for approximately 24 to 48 hours but is not commonly deployed for synthetic cathinones outside of specialized forensic settings.
Hair Follicle Detection
Hair analysis can detect synthetic cathinones including Butylone for up to 90 days. Incorporation into the hair shaft follows standard pharmacokinetic principles for basic amines. However, most commercial hair testing panels do not specifically target Butylone, requiring custom LC-MS/MS methods with appropriate reference standards.
Confirmatory Testing
Definitive identification of Butylone requires instrumental analysis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method for synthetic cathinones due to their thermal lability, which can cause degradation during gas chromatography. GC-MS remains usable but may require derivatization for optimal sensitivity. Reference standards specific to Butylone are necessary for quantitative confirmation.
Reagent Testing
Marquis reagent typically produces no reaction or a faint yellow-orange color with Butylone. Mecke reagent may show no significant color change. Mandelin reagent can produce a yellow to brown reaction. The lack of strong, characteristic color reactions with common reagents makes cathinone identification by reagent testing alone unreliable. A combination of Marquis, Mecke, Mandelin, and Simon's reagents can help rule out other substance classes but cannot positively confirm Butylone.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Chemical Development
Butylone was first synthesized and characterized as part of Alexander Shulgin's systematic exploration of the phenethylamine chemical space, documented in his 1991 reference work PiHKAL: A Chemical Love Story. Shulgin synthesized MBDB — the non-beta-ketone parent of butylone — and characterized its entactogenic properties. The beta-ketone (cathinone) modification introducing butylone was described subsequently.
Emergence as a Novel Psychoactive Substance
Like other MDxx cathinones, butylone emerged in online research chemical markets in the late 2000s and early 2010s. It appeared in contexts related to the broader "bath salts" NPS market alongside methylone, ethylone, and mephedrone, and was documented in seizure analyses and forensic drug databases across Europe, North America, and Australia during this period.
Regulatory Status
Butylone has been controlled in numerous jurisdictions. In the United States, it was placed in Schedule I via emergency scheduling in 2012 and permanently scheduled in 2014. The UK, EU member states, and Australia have implemented similar controls under their respective NPS or cathinone-specific legislation. In some jurisdictions, it falls under analog laws without explicit listing.
Scientific Interest
Butylone has been the subject of pharmacological research characterizing the MDxx cathinone class, and has appeared in case reports and forensic analyses documenting the NPS landscape of the 2010s. Its intermediate position between stimulant and entactogen has made it a useful comparator compound in studies examining the role of SERT:DAT ratio in determining the character of monoaminergic drug effects.
Harm Reduction
Test Your Substance
Butylone cannot be distinguished from MDMA by appearance. Reagent testing is essential:
- Marquis reagent: Butylone typically produces orange to brown (MDMA produces purple to black — a meaningful difference)
- Mecke reagent: Butylone typically produces blue-green
- Simon's reagent: A secondary amine indicator — MDMA is positive, N-methyl cathinones like butylone may vary; useful for distinguishing compound classes
Dose Conservatively
Butylone is less potent than MDMA, meaning the dosing equivalence is not 1:1. Without laboratory quantification, start at a conservative dose and wait for full onset before reassessing:
- Allow 90 minutes from oral ingestion before considering redosing
- Redosing cathinone entactogens carries elevated cardiovascular and serotonergic risk
Spacing and Frequency
MDMA harm reduction guidelines recommend spacing use by at least 1–3 months; butylone warrants similar respect:
- The serotonergic component means recovery time is needed between sessions
- Frequent use accelerates tolerance and increases neurotoxic risk
Environment and Overheating
If using in a dance or social environment:
- Take regular breaks from physical activity
- Maintain adequate hydration — but do not over-hydrate (hyponatremia risk with entactogens)
- Monitor body temperature; overheating is a serious and underrecognized risk
Dangerous Combinations
- MAOIs: Absolutely contraindicated
- Other entactogens/MDMA: Additive serotonin syndrome risk
- Stimulants: Additional cardiovascular strain
- Lithium: Increased seizure and adverse event risk
- Tramadol: Serotonin syndrome risk
Awareness of Purity and Adulterants
Cathinones sold under various names in unregulated markets are frequently mislabeled or of uncertain purity. This is particularly important with butylone, which may be sold as MDMA (and vice versa) with dramatically different dosing implications.
Toxicity & Safety
Overview
Butylone's toxicity profile combines elements of entactogen and stimulant risk. As a less potent, less extensively researched MDxx cathinone analog, the full scope of its hazards is less well characterized than MDMA.
Cardiovascular Risk
Butylone produces sympathomimetic cardiovascular effects through norepinephrine and dopamine reuptake inhibition: elevated heart rate, increased blood pressure, peripheral vasoconstriction. These effects are generally milder than with more purely dopaminergic cathinones like A-PVP, but remain meaningful, particularly at higher doses or in combination with other stimulants.
Serotonin Syndrome Risk
As a serotonin releaser/reuptake inhibitor, butylone can contribute to serotonin syndrome when combined with other serotonergic agents. This risk is highest in combination with MAOIs — a combination that is absolutely contraindicated and potentially life-threatening. Caution is warranted with SSRIs, SNRIs, other entactogens, tramadol, and lithium.
Hyperthermia
Like other entactogens, butylone can cause hyperthermia, particularly during physical exertion, in hot/crowded environments, or at high doses. Dance environments are a particular risk factor.
Neurotoxicity
MDMA is known to cause serotonergic neurotoxicity with repeated heavy use. MDxx cathinones including butylone share a broadly similar pharmacological mechanism, and while butylone-specific neurotoxicity data in humans is sparse, the prudent assumption is that similar risks apply, particularly with frequent or high-dose use.
Drug Interactions
- MAOIs: Absolutely contraindicated — risk of severe serotonin syndrome
- Lithium: Increased risk of adverse events
- Other entactogens: Additive serotonin syndrome risk
- Stimulants: Additive cardiovascular effects
- Tramadol: Lowers seizure threshold, serotonin syndrome risk
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from Butylone is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Austria: Butylone is illegal to possess, produce and sell under the NPSG (New Psychoactive Substances Act).
Brazil: As of September 7, 2018, all cathinone analogues are controlled substances considered illegal to possess, use and distribute. This was made possible due to a blanket ban law appended to Portaria SVS/MS nº 344.
Canada: Butylone is controlled as a Schedule I substance.
China: As of October 2015 butylone is a controlled substance in China.
Finland: Butylone is a controlled substance.
France: Butylone is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.
Germany: Butylone is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of July 26, 2012. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Israel: Butylone is a controlled substance.
Japan: Butylone is a controlled substance.
Norway: Butylone is a controlled substance.
Poland: Butylone is a controlled substance.
Sweden: Butylone is a Schedule I controlled substance as of February 1, 2010.
Switzerland: Butylone is a controlled substance specifically named under Verzeichnis D.
United Kingdom: Butylone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.
United States: Butylone is unscheduled in the United States. However it could be considered an analog of methylone or MDMA, thus making it illegal under the scope of the Federal Analog Act.
Responsible use
Entactogens
Stimulants
Substituted cathinone
Methylone
Butylone (Wikipedia)
Butylone (Erowid Vault)
Butylone (Isomer Design)
BK-MBDB (Bluelight)
Tips (5)
Start low with Butylone and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Weigh your dose of Butylone with a milligram scale. Street stimulants vary wildly in purity and potency. What looks like a normal amount could be significantly stronger than expected, especially with a new batch.
Do not take Butylone in the afternoon or evening if you want to sleep that night. Most stimulants have long half-lives and even if you feel you can sleep, the quality will be significantly impaired.
Monitor your heart rate and blood pressure when using Butylone. Sustained elevated cardiovascular stress causes cumulative damage. If you experience chest pain, irregular heartbeat, or numbness in extremities, seek medical attention.
If you snort Butylone, use a clean straw (never shared), crush the powder as finely as possible, alternate nostrils, and rinse with saline spray after your session. Chronic insufflation damages nasal tissue and septum.
See Also
References (5)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- MDMA-assisted therapy for PTSD — Mithoefer et al. Psychopharmacology (2019)paper
- PubChem: Butylone
PubChem compound page for Butylone (CID: 56843046)
pubchem - Butylone - TripSit Factsheet
TripSit factsheet for Butylone
tripsit - Butylone - Wikipedia
Wikipedia article on Butylone
wikipedia